KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 74 filers reported holding KALVISTA PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $384,000 | +69.2% | 39,048 | +127.9% | 0.02% | +21.4% |
| Q4 2021 | $227,000 | -32.0% | 17,131 | -10.5% | 0.01% | -48.1% |
| Q3 2021 | $334,000 | +110.1% | 19,138 | +45.3% | 0.03% | +145.5% |
| Q2 2020 | $159,000 | -13.1% | 13,169 | -16.6% | 0.01% | -31.2% |
| Q3 2019 | $183,000 | – | 15,799 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,810,246 | $17,432,669 | 7.30% |
| TCG Crossover Management, LLC | 3,395,495 | $32,698,617 | 4.82% |
| TANG CAPITAL MANAGEMENT LLC | 3,440,345 | $33,130,522 | 4.68% |
| VR Adviser, LLC | 2,916,667 | $28,087,503 | 2.96% |
| Frazier Life Sciences Management, L.P. | 3,238,859 | $31,190,212 | 2.07% |
| Nan Fung Group Holdings Ltd | 234,573 | $2,258,938 | 1.83% |
| DAFNA Capital Management LLC | 605,532 | $5,831,273 | 1.81% |
| Opaleye Management Inc. | 500,000 | $4,815,000 | 1.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 530,400 | $5,107,752 | 1.55% |
| MPM BioImpact LLC | 577,958 | $5,565,736 | 1.49% |